EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 38 / Numéro 2 (Février 2022) Med Sci (Paris), 38 2 (2022) 177-181 Références
Contraception
Accès gratuit
Numéro
Med Sci (Paris)
Volume 38, Numéro 2, Février 2022
Contraception
Page(s) 177 - 181
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2022002
Publié en ligne 18 février 2022
  1. March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010 ; 25 : 544–551. [CrossRef] [PubMed] [Google Scholar]
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 ; 81 : 19–25. [Google Scholar]
  3. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016 ; 31 : 2841–2855. [CrossRef] [PubMed] [Google Scholar]
  4. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 2015 ; 149 : R219–R227. [CrossRef] [PubMed] [Google Scholar]
  5. Ollila MM, West S, Keinanen-Kiukaaniemi S, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus-a prospective population-based cohort study. Hum Reprod 2017 ; 32 : 968. [CrossRef] [PubMed] [Google Scholar]
  6. Marchesan LB, Spritzer PM. ACC/AHA 2017 definition of high blood pressure : implications for women with polycystic ovary syndrome. Fertil Steril 2019 ; 111 : 579–587. [CrossRef] [PubMed] [Google Scholar]
  7. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016 ; 2 : 16057. [CrossRef] [PubMed] [Google Scholar]
  8. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome : a systematic review and meta-analysis. Hum Reprod Update 2014 ; 20 : 748–758. [CrossRef] [PubMed] [Google Scholar]
  9. Charitidou C, Farmakiotis D, Zournatzi V, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine leves, in women with the polycystic ovary syndrome. Atheroscler 2008 ; 196 : 958–965. [CrossRef] [Google Scholar]
  10. Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018 ; 10 : 364–379. [CrossRef] [PubMed] [Google Scholar]
  11. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 ; 97 : 28–38.e25. [CrossRef] [PubMed] [Google Scholar]
  12. World Health Organization. Combined hormonal oral contraception and risk of venous thromboembolism (VTE). Sexual and reproductive health 2018. http : //www.who.int/reproductivehealth/topics/family_planning/coc/en/. [Google Scholar]
  13. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives : venous thrombosis. Cochrane Database Syst Rev 2014; 3 : CD010813. [Google Scholar]
  14. Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018 ; 141 : 287–294. [CrossRef] [PubMed] [Google Scholar]
  15. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Meta-Analysis Cochrane Database Syst Rev 2019; 2019 (11). [Google Scholar]
  16. World Health Organization. Medical eligibility criteria for contraceptive use, 5th ed. Geneva : WHO, 2015. http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/. [Google Scholar]
  17. Haverinen A, Kangasniemi M, Luiro K, et al. Ethinyl estradiol vs estradiol valerate in combined oral contraceptives - Effect on glucose tolerance : A randomized, controlled clinical trial. Contraception 2021; 103 : 53–9. [CrossRef] [PubMed] [Google Scholar]
  18. Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome : a systematic review and meta-analysis of observational studies. Hum Reprod 2011 ; 26 : 191–201. [CrossRef] [PubMed] [Google Scholar]
  19. Luque-Ramírez M, Nattero-Chávez L. Ortiz Flores AE, Escobar-Morreale HF. Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome : a systematic review and meta-analysis. Hum Reprod Update 2018 ; 24 : 225–241. [CrossRef] [PubMed] [Google Scholar]
  20. Spritzer PM, Motta AB, Sir-Petermann T, Diamanti-Kandarakis E. Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol 2015 ; 40 : 195–212. [PubMed] [Google Scholar]
  21. Mario FM, Graff SK, Spritzer PM. Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS : a cross-sectional study. J Endocrinol Invest 2017 ; 40 : 377–384. [CrossRef] [PubMed] [Google Scholar]
  22. Graff SK, Mario FM, Ziegelmann P, Spritzer PM. Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS : systematic review and meta-analysis. Int J Clin Pract 2016 ; 70 : 450–461. [CrossRef] [PubMed] [Google Scholar]
  23. Zimmermann Y, Eijkemans MJ, Coelingh Benning HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women : a systematic review and meta-analysis. Hum Reprod Update 2014 ; 20 : 76–105. [CrossRef] [PubMed] [Google Scholar]
  24. Eil C, Edelson SK. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab 1984 ; 59 : 51–55. [CrossRef] [PubMed] [Google Scholar]
  25. Maier PS, Mattiello SS, Lages L, Spritzer PM. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities. Gynecol Endocrinol 2012 ; 28 : 606–610. [CrossRef] [PubMed] [Google Scholar]
  26. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. ESE PCOS Special Interest Group. The polycystic ovary syndrome : a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014 ; 171 : P1–29. [CrossRef] [PubMed] [Google Scholar]
  27. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism : a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012 ; 18 : 146–170. [CrossRef] [PubMed] [Google Scholar]
  28. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000 ; 52 : 587–594. [CrossRef] [PubMed] [Google Scholar]
  29. Spritzer PM, Barone CR, Oliveira FB. Hirsutism in Polycystic Ovary Syndrome : Pathophysiology and Management. Curr Pharm Des 2016 ; 22 : 5603–5613. [CrossRef] [PubMed] [Google Scholar]
  30. Savio MC, Fata R, Facchinetti F, Grandi G. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen : a new option for oral contraception. Expert Rev Clin Pharmacol 2020; 13 : 685–94. [CrossRef] [PubMed] [Google Scholar]
  31. Kuttenn F, Rigaud C, Wright F, Mauvais-Jarvis P. Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol. J Clin Endocrinol Metab 1980 ; 51 : 1107–1111. [CrossRef] [PubMed] [Google Scholar]
  32. Mowszowicz I, Wright F, Vincens M, et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem 1984 ; 20 : 757–761. [CrossRef] [PubMed] [Google Scholar]
  33. Graillon T, Boissonneau S, Appay R, et al Meningiomas in patients with long-term exposition to progestins : Characteristics and outcome. Neurochirurgie 2021 : S0028–3770(21)00145–4. [PubMed] [Google Scholar]
  34. Weill A, Nguyen P, Labidi M, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women : cohort study. BMJ 2021; 372 : n37. [CrossRef] [PubMed] [Google Scholar]
  35. Grimes DA, Lopez LM, O’Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev 2013; 11 : CD007541. [Google Scholar]
  36. da Silva AV, de Melo AS, Barboza RP, et al. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects. Reprod Sci 2016 ; 23 : 877–884. [CrossRef] [PubMed] [Google Scholar]
  37. Diamanti-Kandarakis E, Spritzer PM, Sir-Petermann T, Motta AB. Insulin resistance and polycystic ovary syndrome through life. Curr Pharm Des 2012 ; 18 : 5569–5576. [CrossRef] [PubMed] [Google Scholar]
  38. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited : an update on mechanisms and implications. Endocr Rev 2012 ; 33 : 981–1030. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.